Key points are not available for this paper at this time.
Alzheimer’s disease (AD), primarily characterized by progressive cognitive decline, poses a significant global public health challenge. Emerging evidence indicates that mitochondrial dysfunction plays a central role in AD-related neurodegeneration. This dysfunction manifests as impaired energy metabolism and elevated oxidative stress, and it interacts with β-amyloid (Aβ) and phosphorylated tau (p-tau) pathologies, collectively forming a self-reinforcing vicious cycle. This review systematically explores the mechanisms underlying mitochondrial dysfunction in AD and highlights recent advancements in neuroimaging technologies, such as positron emission tomography (PET), magnetic resonance spectroscopy (MRS), and susceptibility-weighted imaging (SWI), for detecting mitochondrial abnormalities and metabolic disturbances. These multimodal imaging modalities enable the in vivo assessment of mitochondrial metabolism, oxidative stress levels, iron deposition, and the integrity of neural networks. Such capabilities not only enhance our understanding of the spatiotemporal progression of mitochondrial pathology in AD but also offer novel tools for early diagnosis, precise patient stratification, and objective evaluation of therapeutic efficacy. Accordingly, this review evaluates the substantial potential of integrating mitochondrial mechanism research with neuroimaging technologies in both foundational research and clinical practice related to AD.
Hu et al. (Fri,) studied this question.